Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547105 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00547105 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT00547105, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving erlotinib together with stereotactic body radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with stereotactic body radiation therapy works in treating patients with locally advanced or metastatic non-small cell lung cancer.
Interventions
- RADIATION SBRT
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-06-25 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547105
The ClinicalTrials.gov registry entry for NCT00547105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SBRT is the first listed.
NCT00547105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547105 about?
NCT00547105 is a clinical study titled "Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving erlotinib together with stereotactic body radiation ther...
What is the current status of trial NCT00547105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2007-06-25. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT00547105?
The interventions under investigation include: SBRT (RADIATION), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00547105?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.